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OBJECTIVE—The AMP-activated protein kinase (AMPK) pathway is a master regulator in
energymetabolismandmayberelatedtocancer.Intype2diabetes,lowHDLcholesterolpredicts
cancer, whereas metformin usage is associated with reduced cancer risk. Both metformin and
apolipoprotein A1 activate the AMPK signaling pathway. We hypothesize that the anticancer
effects of metformin may be particularly evident in type 2 diabetic patients with low HDL
cholesterol.
RESEARCH DESIGN AND METHODS—In a consecutive cohort of 2,658 Chinese type
2diabeticpatientsenrolledinthestudybetween1996and2005,whowerefreeofcancerandnot
using metformin at enrollment or during 2.5 years before enrollment and who were followed
until 2005, we measured biological interactions for cancer risk using relative excess risk as a
result of interaction (RERI) and attributable proportion (AP) as a result of interaction. A statis-
tically signiﬁcant RERI .0o rA P.0 indicates biological interaction.
RESULTS—During 13,808 person-years of follow-up (median 5.51 years), 129 patients de-
veloped cancer. HDL cholesterol ,1.0 mmol/L was associated with increased cancer risk among
those who did not use metformin, but the association was not signiﬁcant among those who did.
UseofmetforminwasassociatedwithreducedcancerriskinpatientswithHDLcholesterol,1.0
mmol/L and, to a lesser extent, in patients with HDL cholesterol $1.0 mmol/L. HDL cholesterol
,1.0 mmol/L plus nonuse of metformin was associated with an adjusted hazard ratio of 5.75
(95% CI 3.03–10.90) compared with HDL cholesterol $1.0 mmol/L plus use of metformin,
with a signiﬁcant interaction (AP 0.44 [95% CI 0.11–0.78]).
CONCLUSIONS—The anticancer effect of metformin was most evident in type 2 diabetic
patients with low HDL cholesterol.
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P
atients with type 2 diabetes have
increased cancer risk, although the
risk association of cancer with anti-
diabetes drugs remains controversial (1).
This is in part attributed to heterogeneity
in causalities, phenotypes, and treatment
responses. In addition to age and smok-
ing status, abnormal lipids are strong
predictors of cancer in type 2 diabetes
(2). Our group has reported a V-shaped
risk association of HDL cholesterol with
cancer, with an optimal level of 1.22
mmol/L and a rapid increase above and
below the optimal point (2). Low HDL
cholesterol is a common feature of type
2 diabetes (3) and obesity, the latter often
considered a linking factor for cancer risk
because of insulin resistance (4). How-
ever, apolipoprotein (Apo) A-I, the main
lipoprotein of HDL cholesterol, also can
stimulate the phosphorylation of AMP-
activated protein kinase (AMPK) and
acetyl-CoAcarboxylase(ACC) to increase
glucose uptake in muscle (5) and insulin
sensitivity.Inthislight,theAMPKpathway
is considered to be a master switch in sens-
ing and regulating energy metabolism by
balancing catabolism (lipolysis) and anabo-
lism (protein and glycogen storage) (6). A
large number of factors can activate or in-
hibittheAMPKsignalingpathway, and one
of these is the upstream signal, LKB1, a
tumor suppressor. In experimental stud-
ies, inhibition of the LKB1-AMPK path-
way results in tumor formation (7),
whereas metformin activates the LKB1-
AMPK pathway and inhibits cancer cell
growth (8). In support of these ﬁndings,
epidemiological studies have reported re-
ducedcancerrisk (9) and associated mor-
tality (10) in type 2 diabetic patients
treated with metformin compared with
other antidiabetes drugs. This study ar-
gued that the anticancer effects of metfor-
min, if any, would be most evident in
patients with low HDL cholesterol.
RESEARCH DESIGN AND
METHODS—We selected a prospec-
tive cohort from the Hong Kong Diabetes
Registry enrolled between 1 December
1996 and 8 January 2005 because drug
dispensary data became fully computer-
izedandavailableforanalysispurposesin
1996. A detailed description of the Hong
Kong Diabetes Registry is available else-
where (11–13). Brieﬂy, the registry was
established at the Prince of Wales Hospi-
tal, the teaching hospital of the Chinese
University of Hong Kong, which serves a
population of .1.2 million. The referral
sources of the cohort included general
practitioners, community clinics, other
specialty clinics, the Prince of Wales Hos-
pital, and other hospitals. Enrolled pa-
tients with hospital admissions within
6–8 weeks prior to assessment accounted
for ,10% of all referrals. A 4-h assess-
ment of complications and risk factors
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ORIGINAL ARTICLEwas performed on an outpatient basis,
modiﬁed from the European DiabCare
protocol (14). Once a patient had under-
gone this comprehensive assessment, he/
she was considered to have entered this
study cohort and would be followed until
the time of death. Ethicalapprovalwasob-
tainedfromtheChineseUniversityofHong
Kong Clinical Research Ethics Committee.
This study adhered to the Declaration of
Helsinki, and written informed consent
was obtained from all patients at the time
of assessment, for research purposes.
By2005,7,387diabeticpatientswere
enrolled in the registry since December
1996. We sequentially excluded 1)3 2 8
patients with type 1 diabetes or missing
data on types of diabetes; 2) 45 patients
with non-Chinese or unknown national-
ity; 3) 175 patients with a known history
of cancer or receiving cancer treatment at
enrollment; 4) 736 patients with missing
values on any variables used in the anal-
ysis(seeTable1foralistofvariables);and
5) 3,445 patients who used metformin
during 2.5 years before enrollment. The
remaining 2,658 patients were included
in the analysis. The cutoff point of 2.5
years was chosen because any duration
longer than that did not lead to any no-
ticeable changes in the hazard ratios
(HRs) and 95% CIs of metformin use for
cancer (Supplementary Table 1).
Clinical measurements and data
retrieval
Patientsattendedthecenterafteran8-hfast
and underwent a 4-h structured clinical
assessment that included laboratory inves-
tigations. A sterile, random-spot urinary
sample was collected to measure albumin-
to-creatinine ratio (ACR). In this study,
albuminuria was deﬁn e da sa nA C R$2.5
mg/mmol in men and $3.5 mg/mmol in
women. The abbreviated Modiﬁcation of
Diet in Renal Disease Study formula recali-
brated for Chinese subjects (15) was used
to estimate glomerular ﬁltration rate (GFR)
(expressed in mL/min per 1.73 m
2): esti-
matedGFR=1863(SCR30.011)
–1.1543
(age)
–0.203 3 (0.742 if female) 3 1.233,
where SCR is serum creatinine expressed
as mmol/L (original mg/dL converted to
mmol/L), and 1.233 is the adjusting coef-
ﬁcient for Chinese subjects. Total choles-
terol, triglycerides, and HDL cholesterol
were measured by enzymatic methods
on a Hitachi 911 automated analyzer
(Boehringer Mannheim, Mannheim, Ger-
many) using reagent kits supplied by the
manufacturer of the analyzer, whereas
LDL cholesterol was calculated using the
Friedewald equation (16). The precision
performance of these assays was within
the manufacturer’s speciﬁcations.
Drug usage data were extracted from
the Hong Kong Hospital Authority Central
Computer System, which recorded all
drug dispensary data in public hospitals,
including the start dates and end dates for
each of the drugs of interest. In Hong
Kong, all medications are dispensed on
Table 1—Clinical and biochemical characteristics of the study cohort stratiﬁed according
to occurrence of cancer during follow-up period
Noncancer (n =2 , 5 2 9 ) C a n c e r( n =1 2 9 ) P
Baseline variables
Age (years) 55 (44–66) 64 (55–72) ,0.0001*
Male sex 1,236 (48.9) 71 (55.0) 0.1718†
Employment status ,0.0001†
Full-time 926 (36.6) 29 (22.5)
Housewife 699 (27.6) 36 (27.9)
Retired 654 (25.9) 58 (50.0)
Other 250 (9.9) 6 (4.7)
Smoking status 0.0046†
Ex-smoker 365 (14.4) 26 (20.2)
Current smoker 390 (15.4) 30 (23.3)
Alcohol intake 0.0030†
Ex-drinker 298 (11.8) 28 (21.7)
Current drinker 198 (7.8) 7 (5.4)
BMI (kg/m
2) 24.3 (22.0–26.5) 23.9 (22.2–26.4) 0.6937*
Duration of diabetes (years) 4 (1–9) 5 (2–12) 0.0180*
SBP (mmHg) 132 (120–146) 134 (125–148) 0.0827*
Diastolic blood pressure (mmHg) 75 (68–82) 75 (67–82) 0.9706*
A1C (%) 6.9 (6.1–8.2) 7.2 (6.1–8.6) 0.2575*
LDL cholesterol (mmol/L) 3.20 (2.60–3.80) 2.30 (2.90–3.74) 0.0154*
HDL cholesterol (mmol/L) 1.26 (1.07–1.52) 1.25 (0.99–1.53) 0.3760*
HDL cholesterol ,1.0 mmol/L 398 (15.7) 35 (27.1) 0.0006
Triglycerides (mmol/L) 1.26 (0.9–1.86) 1.16 (0.84–1.66) 0.0700*
ACR (mg/mmol) 1.54 (0.67–8.54) 3.07 (0.93–11.04) 0.0063*
Albuminuria 968 (38.3) 64 (49.6) 0.0100†
Estimate GFR
(mL/min per 1.73 m
2) 105.5 (84.0–127.7) 99.8 (81.6–118.8) 0.1047*
Events and medications during follow-up§
Death (all-cause) 188 (7.4) 68 (52.4) ,0.0001†
ACE inhibitors or ARBs 1,198 (47.4) 55 (42.6) 0.2933†
Statins 817 (32.3) 17 (13.2) ,0.0001†
Fibrates 206 (8.2) 7 (5.4) 0.2672†
Other lipid-lowering drugs 12 (0.5) 0 (0.0) 1.0‡
Acarbose 143 (9.5) 5 (2.5) 0.3902†
Glibenclamide 537 (21.2) 25 (19.4) 0.6150†
Gliclazide 1,001 (39.6) 41 (31.8) 0.0768†
Glimepiride 15 (0.6) 1 (0.8) 0.5499‡
Glipizide 217 (8.6) 21 (16.3) 0.0028†
Metformin 1,226 (48.5) 40 (31.0) ,0.0001†
Duration of metformin use
(years)j 3.09 (1.21–5.65) 1.21 (0.57–3.57) 0.0008*
Mean daily metformin
dosage (g)j 1.01 (0.82–1.56) 1.05 (0.64–1.42) 0.1981*
Pioglitazone 19 (0.8) 0 (0) 1.0‡
Rosiglitazone 72 (2.8) 1 (0.9) 0.2618‡
Tolbutamide 19 (0.8) 0 (0) 1.0‡
Follow-up time (years) 5.70 (3.23–7.44) 2.52 (1.09–4.51) ,0.0001†
Data are median (25th to 75thpercentile) or n(%). *Derivedfrom Wilcoxontwo-sample test.†Derived from
x
2 test. ‡Derived from Fisher exact test. §From enrollment to the earliest date of cancer, death, or censoring.
jAmong metformin users only.
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HDL cholesterol, metformin, and cancer in diabetessite in both inpatient and outpatient set-
tings. These databases were matched by a
unique identiﬁcation number, the Hong
Kong identity card number, which is com-
pulsory for all residents in Hong Kong.
A trained team at the Hong Kong
Hospital Authority coded all hospital
admissions. All medical admissions of
the cohort from enrollment to 30 July
2005 were retrieved from the Hong Kong
Hospital Authority Central Computer
System, which recorded admissions to
all public hospitals in Hong Kong. Col-
lectively, these hospitals provide 95% of
the total hospital bed-days in Hong Kong
(17). Additionally, mortality data from
the Hong Kong Death Registry during
the period were retrieved and cross-
checked with hospital discharge status.
Hospital discharge principle diagnoses,
coded by the International Statistical
Classiﬁcation of Diseases and Related
Health Problems 9th Revision (ICD-9),
were used to identify cancer events. The
outcome measure of this study was inci-
dent cancer (fatal or nonfatal: codes 140–
208) during the follow-up period.
Statistical analyses
We used biological interactions to test
whether metformin use was associated
with a greater cancer risk reduction in
patientswithlowHDLcholesterolthanin
those with normal or high HDL choles-
terol. The Statistical Analysis System (re-
lease 9.10) was used to perform the
statistical analysis (SAS Institute, Cary,
NC), unless otherwise speciﬁed. Follow-
up time was calculated as the period in
years from the ﬁrst enrollment since 1
December 1996 to the date of the ﬁrst
cancer event, death, or censoring, which-
ever came ﬁrst. Cox proportional hazard
regressionwasusedtoobtaintheHRsand
95% CIs of the variables of interest.
We ﬁrst plotted the full-range associa-
tion of HDL cholesterol and cancer and
further reﬁned cutoff points of HDL cho-
lesterolforcancerriskinthecohortwithout
prevalent metformin users, using restricted
cubic spline Cox models (11). Then,
we examined the biological interaction for
cancer risk between low HDL cholesterol
and nonuse of metformin using three
measures: 1) relative excess risk caused
by interaction (RERI); 2) attributable pro-
portion (AP) caused by interaction; and
3) the synergy index (S) (18). A detailed
calculation method of additive interac-
tion, including the deﬁnition of three in-
dicator variables, an SAS program, and
a calculator in Microsoft Excel (www.
epinet.se), was described by the authors.
The RERI is the excess risk attributed to
interaction relative to the risk without ex-
posure. AP refers to the attributable pro-
portion of disease, which is caused by the
interaction in subjects with both expo-
sures. S is the excess risk from both expo-
sures when there is biological interaction
relative to the risk from both exposures
without interaction. A simulation study
showed that RERI performed best and
AP performed fairly well, but S was prob-
lematic in the measure of additivity in the
proportional hazard model (19). The cur-
rent study reﬁned the criteria as either a
statistically signiﬁcant RERI .0o rA P.0
to indicate biological interactions.
The following two-step adjustment
scheme was used in these analyses: 1)
only adjusting for LDL cholesterol–
related cancer risk indicators (LDL choles-
terol $3.80 mmol/L and LDL cholesterol
,2.80 mmol/L plus albuminuria) (11,12),
triglycerides (2), and high HDL choles-
terol, where appropriate (2), and 2) fur-
ther adjusting for age, sex, employment
status, smoking status, alcohol intake, du-
rationofdiabetes,BMI($27.6and,24.0
kg/m
2) (2), systolic blood pressure (SBP),
and A1C (20) at enrollment and use of
statins (13), ﬁbrates, other lipid-lowering
drugs, ACE inhibitors/angiotensin II re-
ceptor blockers (ARBs) (13), and insulin
(20) during follow-up. Use of drugs dur-
ing follow-up was deﬁned as use of the
drugs from enrollment to cancer, death,
or censoring date, whichever came ﬁrst.
By deﬁnition, the use of any drugs after
the ﬁrst cancer event wascoded as nonuse
of these drugs, and any drug users had
been given at least one prescription of
the drug during follow-up. The total met-
formin dosage divided by the total num-
ber of days during which metformin was
prescribed was used as daily metformin
dosage. We also used propensity score to
adjust for the likelihood of initiation of
metformin during the follow-up period
(21). The former was obtained using a lo-
gistic regression procedure that includes
the following independent variables: age;
sex;BMI;LDLcholesterol;HDLcholesterol;
triglycerides; tobacco and alcohol intake;
A1C; SBP; ln (ACR + 1); estimated GFR;
peripheral arterial disease; retinopathy;
sensoryneuropathy;andhistoryofcardio-
vascular disease (coronary heart disease,
myocardialinfarction, and stroke) atbase-
line (c statistics = 0.73). We then used
stratiﬁed Cox models on deciles of the
score to adjust for the likelihood of met-
formin use.
Sensitivity analyses were performed
to address 1) the impacts of undiagnosed
cancer by limiting the analysis to patients
who were followed for $2.5 years (n =
2170); 2) the impact of incomplete exclu-
sion of patients who used metformin
during 2.5 years before enrollment by
limiting the analysis to patients who
were enrolled on or after 1 July 1998
(n = 1707); 3) the impact of prevalent
bias by reinclusion of 3,445 patients
who used metformin during 2.5 years be-
fore enrollment; and 4) inclusion of sub-
jects with missing values in univariable
analysis and without adjusting for the
propensity score to maximize the valid
sample size (n of the valid sample size =
2,996 and n of the sample size with miss-
ing values in HDL cholesterol = 53 [i.e.,
1.74% missing-value rate]).
RESULTS
Characteristics of the patients
Themedianageofthecohortwas56years
(25th to 75th percentiles [interquartile
range {IQR} 45–67]) at enrollment. Dur-
ing 13,808 person-years of follow-up
(5.51years[3.08–7.39]),129patientsde-
veloped cancer. In the cohort, 16.3% (n =
433) of patients had low HDL cholesterol
,1.0 mmol/L and 46.7% (n = 1,243) had
HDL cholesterol $1.30 mmol/L. Patients
with low HDL cholesterol were more
likely to use insulin, develop cancer, and
die prematurely. Patients who developed
cancer were older, more likely to use to-
baccoandalcohol,andhadlongerdisease
duration. They had high LDL cholesterol,
low HDL cholesterol, and albuminuria
and were more likely to have premature
death than those free of cancer. Patients
who developed cancer were less likely
to use statins and metformin during the
follow-up period than patients without
cancer (Table 1).
HDL cholesterol and cancer
Compared with patients with HDL cho-
lesterol $1.0 but ,1.3 mmol/L, patients
with HDL cholesterol ,1 . 0m m o l / L( H R
2.22 [95% CI 1.38–3.58]) and those with
HDL cholesterol $1.3 mmol/L (1.61
[1.05–2.46]) had increased cancer risk
in univariable analysis. After adjusting
for other covariates (Supplementary Fig.
1), HDL cholesterol ,1 . 0m m o l / Lf o r
cancer remained signiﬁcant (2.41 [1.46–
3.96]) but not HDL cholesterol $1.3
mmol/L (P = 0.1197). Additional sub-
group univariable and multivariable anal-
yses indicate that low HDL cholesterol
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Yang and Associateswas associated with increased cancer risk
only among those who did not use met-
formin but not among those who did
(power = 0.37) (Table 2).
Use of metformin and cancer
Use of metformin was associated with a
decreased risk of cancer in a dose-
response manner. After adjusting for co-
variates, patients with HDL cholesterol
,1.0 mmol/L and who were not treated
with metformin had a 5.8-fold risk of
cancer compared with the referent group,
who had HDL cholesterol $1.0 and used
metformin.PatientswithHDLcholesterol
$1.0 mmol/L but who were not treated
with metformin also had higher cancer
risk than the referent group. However,
the cancer risk associated with HDL cho-
lesterol ,1 . 0m m o l / Lw a sr e n d e r e dn o n -
signiﬁcant among those who used
metformin (Table 2 and Supplementary
Fig.2).There wasasigniﬁcant interaction
betweenlowHDLcholesterolandnonuse
of metformin for cancer risk, after adjust-
ingforcovariates(AP0.44[95%CI0.11–
0.78]) (Table 3).
Consistently, the copresence of HDL
cholesterol ,1.0 mmol/L and nonuse of
metformin was associated with an in-
creased risk of cancer at sites other than
the digestive organs and peritoneum and,
to a lesser degree, cancers of the digestive
organs and peritoneum. Copresence of
both factors also was associated with an
increased risk of fatal cancer and, to a
lesser degree, nonfatal cancer (Table 4).
Sensitivity analyses
The series of sensitivity analyses showed a
consistent trend toward an interactive
effect of nonuse of metformin and HDL
cholesterol ,1.0 mmol/L on the risk of
cancer, althoughnot allinteractions inthese
sensitivity analyses reached statistical signif-
icance (Supplementary Tables 2 and 3).
CONCLUSIONS—In this study, we
observed that HDL cholesterol ,1.0
mmol/L and nonuse of metformin was
associated with a 5.8-fold cancer risk
compared with metformin users with
HDL cholesterol $1.0 mmol/L. The sig-
niﬁcant additive interaction indicates that
the increased cancer risk as a result of a
combination of nonuse of metformin and
HDL cholesterol ,1.0 mmol/L was more
than the addition of the risks attributed to
thepresenceofeithernonuseofmetformin
or low HDL cholesterol alone. In other
words, the signiﬁcant interaction suggests
that the use of metformin may confer an
extra cancer beneﬁt in type 2 diabetic pa-
tients with low HDL cholesterol.
Although there are ongoing debates
about the associations between insulin
usage and cancer in diabetes, epidemio-
logical studies have consistently found
that the use of metformin is associated
with reduced cancer risk. Among these
studies, Libby et al. (9) reported that met-
formin use was associated with a 54%
(95% CI 47–60) lower crude incidence
and a 37% (25–47) lower adjusted inci-
dence of cancer than metformin nonusers
over a period of 10 years. In support of
theseﬁndings,wealsofounda50%lower
adjusted cancer risk among metformin
users with HDL cholesterol $1.0 mmol/
L and a 72% lower adjusted risk among
metformin users with HDL cholesterol
,1.0 mmol/L.
Several lines of evidence support the
pivotal role of AMPK, which can be
Table 2—HRs of different combinations of low HDL cholesterol and metformin use for
cancer risk in type 2 diabetes
Exposures n at risk HR (95% CI) P
HDL cholesterol ,1.0 vs. $1.0 mmol/L
Among metformin nonusers
Model 1* 200 2.87 (1.57–5.25) 0.0006
Model 2*† 200 2.99 (1.60–5.61) 0.0006
Among metformin users
Model 3* 233 1.66 (0.72–3.87) 0.2367
Model 4*† 233 1.61 (0.66–3.92) 0.2969
Average daily metformin dose in the
whole cohort (per g)
Model 5*‡ 1,266 0.44 (0.32–0.62) ,0.0001
Model 6*†‡ 1,266 0.50 (0.35–0.71) ,0.0001
Metformin users vs. nonusers
Among patients with HDL
cholesterol $1.0 mmol/L
Model 7*‡ 1,033 0.46 (0.28–0.74) 0.0013
Model 8*†‡ 1,033 0.51 (0.31–0.82) 0.0059
Among patients with HDL
cholesterol ,1.0 mmol/L
Model 9*‡ 233 0.29 (0.13–0.61) 0.0013
Model 10*†‡ 233 0.30 (0.13–0.70) 0.0052
Biological interaction models
Model 11*‡
HDL cholesterol ,1 . 0m m o l / Lp l u s
nonuse of metformin 200 6.18 (3.35–11.40) ,0.0001
HDL cholesterol $1 . 0m m o l / Lp l u s
nonuse of metformin 1,192 2.35 (1.47–3.75) 0.0003
HDL cholesterol ,1 . 0m m o l / Lp l u s
use of metformin 233 1.83 (0.87–3.88) 0.1140
HDL cholesterol $1 . 0m m o l / Lp l u s
use of metformin 1,033 Reference
Model 12*†‡
HDL cholesterol ,1 . 0m m o l / Lp l u s
nonuse of metformin 200 5.75 (3.03–10.90) ,0.0001
HDL cholesterol $1 . 0m m o l / Lp l u s
nonuse of metformin 1,192 2.17 (1.35–3.49) 0.0013
HDL cholesterol ,1 . 0m m o l / Lp l u su s e
of metformin 233 2.02 (0.94–4.35) 0.0855
HDL cholesterol $1 . 0m m o l / Lp l u su s e
of metformin 1,033 Reference
*Adjusted for LDL cholesterol–related risk indicators (LDL cholesterol $3.8 mmol/L and LDL cholesterol
,2.8mmol/Lplusalbuminuria),HDLcholesterol$1.30mmol/L(notformodels7and8),andthenonlinear
association of triglycerides with cancer. †Further adjusted for age, sex, employment status, smoking status,
alcohol intake, duration of diabetes, BMI ($27.6 or ,24.0 kg/m
2), A1C, and SBP at enrollment and use of
statins, ﬁbrates, other lipid-lowering drugs, ACE inhibitors/ARBs, and insulin during follow-up. ‡Stratiﬁed
Cox model analyses on deciles of the propensity score of metformin use were included in models 5–12 to
control for the likelihood of starting metformin therapy during follow-up.
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HDL cholesterol, metformin, and cancer in diabetestriggered by a large number of upstream
signals, in maintaining energy homeosta-
sisbyprovidingabalancebetweenenergy
expenditure through lipolysis and energy
storage through protein and glycogen
synthesis. Activation of AMPK by the
tumor suppressor, LKB1, promotes glu-
cose uptake, increases fatty acid oxida-
tion, and reduces protein and lipid
synthesis. Metformin is known to activate
the AMPK pathway, possibly through the
activation of the LKB1 suppressor gene
(22). On the other hand, hyperglycemia
can downregulate ApoA-I gene transcrip-
tion, which is the major lipoprotein com-
ponent ofHDLlipidparticles (23).In this
regard, ApoA-I has been shown to stimu-
late phosphorylation of AMPK and ACC
(5). More recently, Kimura et al. (24) re-
ported that HDL can activate AMPK
through binding to both sphingosine
1-phosphate receptors/Gi proteins and
scavenger receptor class B type I (SR-BI)/
protein PDZK1, with LKB1 being in-
volved in the SR-BI signaling. Given the
close relationship between HDL choles-
terol and the AMPK pathway, the interac-
tive effects between metformin use and
HDL cholesterol on cancer risk is thus
plausible.
Several limitations in the study have
been noticed. 1) A single measurement of
HDL cholesterol was used in the analysis.
2) Hospital principle discharge diagnosis
was used to retrieve cancer events in the
cohort, and this approach may have
missed a small number of cancer events.
3) The use of drug dispensary data are an
indirect method and may overestimate
exposure because drug acquisition is
only a surrogate marker for actual drug
consumption. Although our deﬁnition
of drug use should not introduce major
bias(25),someunmeasuredconfounding
factorsmayexist.4)Thesamplesizeofthe
study was not large enough to address
whether there were sex-speciﬁcc u t o f f
points of HDL cholesterol for the risk of
cancer. 5) There were insufﬁcient num-
bers of patients/events to explore the re-
lationships between HDL cholesterol
status, metformin exposure, and risk of
speciﬁc cancers. 6) RERI did not reach
statistical signiﬁcance. However, RERIs
were signiﬁcant in sensitivity analyses 3
and 4 with larger sample sizes, suggesting
that the marginallysigniﬁcantRERIinthe
analysis is possibly attributed to insufﬁ-
cient power. 7) These ﬁndings were only
derived froma Chinese cohort and need to
be replicated in other ethnic populations.
In conclusion, the use of metformin
might confer stronger beneﬁts in reducing
cancer risk in patients with HDL choles-
terol ,1.0 mmol/L. Although low HDL
cholesterol is not an indication for metfor-
min usage, if our ﬁndings can be indepen-
dently replicated, patients with low HDL
cholesterol with or without type 2 diabetes
might be candidate subjects for clinical
trials that formally test the anticancer
effects of metformin or agents that mod-
ulate the ApoA-I–LKB1–AMPK pathway.
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Measures of biological interaction Estimate (95% CI) P
Between HDL cholesterol ,1.0 mmol/L and nonuse of metformin
Model 1*†
RERI 3.00 (20.14 to 6.14) 0.0611
AP 0.49 (0.18–0.79)‡ 0.0017
S 2.38 (1.07–5.28) 0.1091
Model 2*†‡
RERI 2.55 (20.49 to 5.60) 0.0999
AP 0.44 (0.11–0.78)‡ 0.0105
S 2.17 (0.94–4.99) 0.1331
*Adjusted for LDL cholesterol–related risk indicators (LDL cholesterol $3.8 mmol/L and LDL cholesterol
,2.8 mmol/L plus albuminuria), HDL cholesterol $1.30 mmol/L, and the nonlinear association of tri-
glyceride with cancer. †Further adjusted for age, sex, employment status, smoking status, alcohol intake,
durationofdiabetes,BMI($27.6or,24.0kg/m
2),A1C,andsystolicbloodpressureatenrollmentanduseof
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cancers
Number
of cancers HR (95% CI)* P
Cancer subtypes†
1) Lip, oral cavity, and pharynx 6
2) Respiratory and intrathoracic organs 16
3) Genitourinary organs 16
4) Lymphatic and hematopoietic tissue 19
5) Bone, connective tissue, skin, and breast 7
6) Other and unspeciﬁed sites 19
Cancer at sites other than digestive organs
and peritoneum (1–6 combined) 77 4.06 (2.39–6.89) ,0.0001
7) Digestive organs and peritoneum 65 2.31 (1.17–4.54) 0.0153
Fatal and nonfatal cancers‡
Fatal cancer 56 3.42 (1.80–6.49) 0.0002
Nonfatal cancer 119 2.70 (1.67–4.37) ,0.0001
*Univariable Cox models with stratiﬁcation on deciles of the propensity score of use of metformin during
follow-upwereusedtoobtaintheHRs.†ClassiﬁcationwasbasedontheICD-9(thereareoverlapsamongsite-
speciﬁc cancers). ‡46 nonfatal cancer events developed before fatal cancer.
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